Borden Ladner Gervais LLP (BLG)’s Post

RenovoRx (Nasdaq: RNXT) CEO, Shaun R. Bagai, highlights the Company's strong IP portfolio with 18 issued patents and 13 pending patents as it moves forward with commercialization plans for RenovoCath and the advancement of the pivotal Phase III TIGeR-PaC clinical trial. Read more: https://bit.ly/40d4yIB

RenovoRx (Nasdaq: RNXT) CEO, Shaun R. Bagai, highlights the Company's strong IP portfolio with 18 issued patents and 13 pending patents as it moves forward with commercialization plans for RenovoCath and the advancement of the pivotal Phase III TIGeR-PaC clinical trial. Read more: https://bit.ly/40d4yIB

Audax to Acquire Avantor's Clinical Services for $650M! Audax Group will acquire Avantor's clinical services business for $650 million, underlining the growing interest in the fragmented clinical trials space. The investment is projected to generate $200 million in revenue this year, and the deal will close in Q4, pulling in $475 million cash for Avantor. #LifeSciences #ClinicalTrials #MergersAndAcquisitions #LifeSciencesRecruitment #ClinicalServices

Merit Medical Systems, Inc. has announced its latest strategic move by acquiring Cook Medical’s lead management device portfolio for $210 million. This significant acquisition underscores Merit’s commitment to expanding its offerings and enhancing its support for cardiac intervention patients. The deal is expected to close in Q4 2024, with Merit Medical leveraging cash reserves and long-term credit for the purchase. CEO Fred P. Lampropoulos highlighted that this acquisition aligns with Merit’s growth strategy and will enable the company to offer a more comprehensive range of solutions from diagnosis to post-procedure care. Cook Medical’s lead management portfolio, which has generated $37 million in revenue in 2023, is a valuable addition. The portfolio has a strong presence in the U.S. and EMEA regions. The transaction is pending antitrust approval but includes a transition agreement with Cook Medical for continued support over the next two years. In addition to this acquisition, Merit Medical recently acquired the rights to the EsophyX Z+ device from EndoGastric Solutions for $105 million. #MedTech #HealthcareInnovation #Acquisition #MeritMedical #InterventionalRadiology #CardiacCare

SELEON GMBH BECOMES PART OF THE AESCO SOLUTIONS GROUP🚀 On May 17, 2024, aesco SOLUTIONS, a leading group for production and development services (#CDMO) for medical device companies, and D11Z. Ventures GmbH & Co. KG (formerly Zukunftsfonds Heilbronn) announce the closing of the acquisition of seleon GmbH. With the acquisition of seleon GmbH, medical device manufacturers will receive from the aesco solutions an even more comprehensive support in the future. By expanding the service offerings and strengthening technological expertise, customers will have the opportunity to bring their medical devices to market faster and more cost-effectively, as complex and cost-intensive interfaces between service providers in the areas of #development, #regulatory & #clinicalaffairs, #qualitymanagement, #industrialization, #production and after-sales services will be eliminated.  „We are very pleased to welcome seleon to the aesco solutions group," says Peter Molnar, CEO of the aesco solutions group. "The acquisition is an important step in the implementation of our buy-and-build strategy to create a leading company in the European #MedTech #CDMO market. We will be able to offer our customers even more innovative and efficient solutions. Together, we want to help to shape the future of the industry by combining application and technology innovations." The takeover of seleon GmbH by the aesco SOLUTIONS Group stands for the continuity of both companies for quality and progress in the medical technology industry and already promises a bright future today. Further information can be found in our press release.

OUR portfolio company VVT Medical in the process of listing on the Toronto Stock Exchange DXI CAPITAL CORP. ANNOUNCES PROPOSED ACQUISITION OF VVT Medical MED LTD. AND EXITEAM ACQUISITION CORP. DXI Capital Corp. has entered into a non-binding letter of intent dated Nov. 22, 2023, with V.V.T. Med Ltd. (VVT), an Israeli corporation, and Exiteam Acquisition Corp. (EAC), a British Columbia corporation, pursuant to which DXI has agreed to acquire all of the issued and outstanding shares in the capital of VVT and EAC as well as all other issued securities of VVT and EAC upon the terms and conditions set out in a definitive agreement to be entered into by the parties. The proposed transaction is expected to enable DXI to meet the initial listing requirements of the TSX Venture Exchange for the reactivation of DXI. Following the completion of the proposed transaction, DXI (the resulting issuer) will continue the business of VVT, being a new medical treatment for varicose veins, and will be listed on the TSX-V under the life sciences sector. Erez Tetro Oded Orgil 🎗️Robert Hodgkinson Sean Hodgins Dor Sneh

Baird served as exclusive financial advisor to Ad-Tech Medical Instrument Corporation, a portfolio company of ARCHIMED, on its sale to Nihon Kohden Corporation. https://bit.ly/4iho6CM

👁️ 𝐁𝐚𝐮𝐬𝐜𝐡 & 𝐋𝐨𝐦𝐛 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐄𝐥𝐢𝐨𝐬 𝐕𝐢𝐬𝐢𝐨𝐧👁️ Bausch + Lomb have today announced the acquisition of Elios Vision to complement their broad surgical portfolio and strengthen their footing in the glaucoma space. Elios Vision are the developers of ELIOS, the first clinically validates MIGS procedure using an excimer laser. “Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.” ELIOS is currently CE marked and is currently marketed in the EU. The company is in the process of pursuing FDA approval #bausch #elios #glaucoma #acquisition #ophthalmologynews

💰 Quest Diagnostics to acquire Canada-based LifeLabs Medical Laboratory Services for $985m The acquisition builds on an existing relationship between the two companies. LifeLabs has participated in the Quest-led Global Diagnostic Network, over the past five years. Under the terms of the agreement, the US company will acquire 100% of LifeLabs. It intends to fund the acquisition through debt and available cash on hand. The acquisition is expected to be completed by the end of this year, subject to certain customary closing conditions and approvals, including Canadian regulatory approvals. Read more online: https://lnkd.in/exCVWszU 📰 Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

5 Things to Know - Thing 1) Shockwave Medical $SWAV Being Acquired by Johnson & Johnson $JNJ: DKI Takeaway: DKI recommended Shockwave Medical $SWAV to subscribers in December at $190. Our positive thesis was based on an expected takeover for more than $300 per share. Boston Scientific $BSX approached Shockwave last year. They could return to bid again, but given that the $JNJ talks have been public for more than a week and that there’s now a breakup fee, it’s possible but unlikely they re-enter the situation. DKI subscribers made more than 70% in under four months. This is the second DKI portfolio company to be acquired following Houghton Mifflin which was bought for more than 4x DKI’s initial purchase price. If that’s of interest to you, you’re welcome to subscribe. Otherwise, we’ll be happy to keep informing you after the fact. https://lnkd.in/gV5RdcGT